FDA Approves First Prescription Digital Therapy for Major Depression, Rejoyn
By Lori Solomon HealthDay Reporter
THURSDAY, April 4, 2024 -- The U.S. Food and Drug Administration (FDA) has cleared the first prescription digital therapeutic authorized for the adjunctive treatment of major depressive disorder (MDD) symptoms.
The approval is for Rejoyn, a six-week treatment program that can enhance cognitive control of emotion as an adjunct to clinician-managed outpatient care for adult patients with MDD (aged 22 years and older) who are on antidepressant medication.
The approval was based on the 13-week Mirai study, which included 386 participants, aged 22 to 64 years, diagnosed with MDD and on antidepressant medication. Among participants who were randomly assigned to receive either Rejoyn or a sham control app, individuals treated with Rejoyn showed an improvement in depression symptom severity from baseline. Symptom improvement was consistently detected across both patient and clinician-reported scales, including the Montgomery-Åsberg Depression Rating Scale, Patient Health Questionnaire nine-item depression scale, and the Clinical Global Impression-Severity scale. Participants in the Rejoyn group showed continued improvement one month after completing the six-week treatment program. No treatment-related adverse events were seen.
"Rejoyn has a neuromodulatory mechanism designed to act like physical therapy for the brain by delivering personalized, consistent brain-training exercises designed to help improve connections in the brain regions affected by depression," Brian Iacoviello, Ph.D., scientific advisor at Click Therapeutics, said in a statement. "When stronger and more balanced connections are created, the regions of the brain responsible for processing and regulating emotions are better able to work together and symptoms of depression can improve."
Approval of Rejoyn was granted to Otsuka and Click Therapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2024
Read this next
Gender-Affirming Hormone Therapy in Primary Care Tied to Reduced Depressive Symptoms
MONDAY, March 24, 2025 -- Gender-affirming hormone therapy (GAHT) in primary care is associated with lower rates of moderate-to-severe depressive symptoms in U.S. transgender...
Exposure to Maternal Cannabis Use Disorder Ups Risk for Youth Behavioral Disorders
MONDAY, March 24, 2025 -- Children exposed to maternal cannabis use disorder (CUD) during pregnancy and postpartum have an increased risk for later behavioral disorders, according...
Total Injury Death Rate Increased From 2013 to 2021, Followed by Decline
THURSDAY, March 20, 2025 -- The total injury death rate in the United States increased from 2013 through 2021, then declined through 2023, according to a March data brief...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.